US Patent Issued to Novartis on Oct. 7 for "Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa" (Swiss, French Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,150, issued on Oct. 7, was assigned to Novartis AG (Basel, Switzerland).

"Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa" was invented by Pascal Espie (Saint Louis, France), Christian Loesche (Hegenheim, France), Lukas Roth (Riehen, Switzerland), James Rush (Thalwil, Switzerland) and Grazyna Wieczorek (Schonenbuch, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating hidradenitis suppurativa, by employing CD40 antagonists, such as anti-CD40 antibodies."

The patent was filed on Jan. 9, 2020, under Application No. 17/422,075.

*For...